

NATCO PHARMA- Entering the Big League through Multi Pronged Strategy

<https://marketpublishers.com/r/N6E439DA6BFEN.html>

Date: March 2012

Pages: 10

Price: US\$ 140.00 (Single User License)

ID: N6E439DA6BFEN

Abstracts

Natco recently was granted a Compulsory License (CL) for Sorafenib (branded as Nexavar, indicated for liver and kidney cancer) for the Indian market. This allows Natco to market this product in India with almost no generic competition for a market that is ~Rs. 500-700m in India with EBITDA margin of ~70%. More importantly, Natco has 5 such other products ready to be filed for compulsory licenses.

Natco has one of the most lucrative Para IV pipeline in India pharma currently with Para IVs on Copaxone (\$2.8b in US), Revlimid (\$1.8b in US), Tamiflu (\$ 250m in US), Tykerb (\$115m) and Fosrenol (\$ 90m). Of these, Natco enjoys FTF status on Revlimid, Tamiflu, Fosrenol and Tykerb. As for generic Copaxone, we believe that clinical trials will not be required for final approval. We recommend Natco as Outperform with a target price of Rs. 445.

Contents

COMPANIES MENTIONED

NATCO PHARMA

I would like to order

Product name: NATCO PHARMA- Entering the Big League through Multi Pronged Strategy

Product link: <https://marketpublishers.com/r/N6E439DA6BFEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N6E439DA6BFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970